Enovis Corporation (ENOV)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Apr 3, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	1.30B	1.30B	1.25B
United States Revenue Growth	0.03%	3.99%	8.10%
Foreign Locations Revenue	982.67M	952.72M	861.95M
Foreign Locations Revenue Growth	3.14%	10.53%	55.35%
Revenue (Other)	5.00K	4.00K	-7.00K
Revenue (Total)	2.28B	2.25B	2.11B
Revenue (Total) Growth	1.35%	6.66%	23.46%

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Apr 3, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
U.S. Bracing & Support Revenue	486.04M	486.24M	469.32M
U.S. Bracing & Support Revenue Growth	-0.04%	3.61%	2.89%
U.S. Other P&R Revenue	260.88M	271.64M	270.74M
U.S. Other P&R Revenue Growth	-3.96%	0.33%	0.34%
International P&R Revenue	389.49M	379.09M	357.90M
International P&R Revenue Growth	2.74%	5.92%	2.02%
Total Prevention & Recovery Revenue	1.14B	1.14B	1.10B
Total Prevention & Recovery Revenue Growth	-0.05%	3.55%	1.97%
U.S. Reconstructive Revenue	548.79M	537.46M	505.62M
U.S. Reconstructive Revenue Growth	2.11%	6.30%	18.58%
International Reconstructive Revenue	593.18M	573.62M	504.05M
International Reconstructive Revenue Growth	3.41%	13.80%	147.06%
Total Reconstructive Revenue	1.14B	1.11B	1.01B
Total Reconstructive Revenue Growth	2.78%	10.04%	60.16%
Total Medical Technology Revenue	2.28B	2.25B	2.11B
Total Medical Technology Revenue Growth	1.35%	6.66%	23.46%
Revenue (Total)	2.28B	2.25B	2.11B
Revenue (Total) Growth	1.35%	6.66%	23.46%

Adjusted EBITDA

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Apr 3, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Prevention & Recovery Adjusted EBITDA	163.30M	163.09M	159.60M
Prevention & Recovery Adjusted EBITDA Growth	0.13%	2.19%	4.65%
Reconstructive Adjusted EBITDA	244.09M	239.91M	216.92M
Reconstructive Adjusted EBITDA Growth	1.75%	10.60%	85.84%
Operating Income (Total)	-21.18M	-1.12B	-775.72M

Capital Expenditures

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Prevention & Recovery Capital Expenditures	28.86M	34.00M
Prevention & Recovery Capital Expenditures Growth	-15.12%	29.02%
Reconstructive Capital Expenditures	168.51M	146.71M
Reconstructive Capital Expenditures Growth	14.86%	53.03%
Total Medical Technology Capital Expenditures	197.38M	180.71M
Total Medical Technology Capital Expenditures Growth	9.22%	47.86%

Data Source: Fiscal.ai Last updated: May 7, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 9, 2026

Data Sources Report a data error